WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Search Results -

Terms	Documents
EUGENOL AND CANCER AND PHARMACEUTICAL	41

Database: US Patents Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Refine Search: L4 AND EUGENOL.CLM. AND EUGENOL.TI.

Clear

Search History

Today's Date: 1/17/2001

DB Name	Query	Hit Count	Set Name
USPT,JPAB,EPAB,DWPI,TDBD	EUGENOL AND CANCER AND PHARMACEUTICAL	41	L4
USPT,JPAB,EPAB,DWPI,TDBD	EUGENOL NEAR10 PHARMACEUTICAL	5	L3
USPT,JPAB,EPAB,DWPI,TDBD	EUGENOL NEAR10 CANCER AND PHARMACEUTICAL	0	L2
USPT,JPAB,EPAB,DWPI,TDBD	EUGENOL NEAR10 CANCER NEAR20 PHARMACEUTICAL	0	L1

L12 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2001 ACS
AN 1998:101607 CAPLUS
DN 128:213361
TI Antianaphylactic properties of eugenol
AU Kim, Hyung-Min; Lee, Eun-Hee; Kim, Chang-Young; Chung, Jong-Gab; Kim, Sang-Hyun; Lim, Jong-Pil; Shin, Tae-Yong
CS Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, Chonbuk, 570-749, S. Korea
SO Pharmacol. Res. (1997), 36(6), 475-480
CODEN: PHMREP; ISSN: 1043-6618
PB Academic Press Ltd.
DT Journal
LA English
CC 1-12 (Pharmacology)
AB The effects of eugenol, a major component of clove, on anaphylaxis were evaluated in rats. Eugenol inhibited compd. 48/80-induced systemic anaphylaxis 100% with a dose of 10 .mu.g g-1 body wt. (BW). While serum levels of histamine were markedly elevated after compd. 48/80 injection in all groups of rats, rats injected with eugenol showed a significant redn. in serum histamine levels. Eugenol also inhibited passive cutaneous anaphylaxis activated by anti-dinitrophenyl (DNP) IgE. Eugenol dose-dependently inhibited histamine release from the rat peritoneal mast cells (RPMC) activated by compd. 48/80 or anti-DNP IgE. The morphol. examn. clearly showed that eugenol prevented the anaphylactic degranulation of RPMC. Moreover, eugenol (10 .mu.g ml-1) had a significant inhibitory effect on anti-DNP IgE-induced tumor necrosis factor-.alpha. prodn. These results suggest that eugenol has antianaphylactic properties by preventing mast cell degranulation.
ST antianaphylactic eugenol
IT Natural products (**pharmaceutical**)
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(anti-anaphylactic activity of **eugenol**)
IT Mast cell degranulation
(eugenol anti-anaphylactic activity in relation to inhibition of)
IT Tumor necrosis factor .alpha.
RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(eugenol anti-anaphylactic activity in relation to inhibition of mast cell formation of)
IT Anaphylaxis
(eugenol as inhibitor of)
IT Hypersensitivity
(type I; anti-anaphylactic activity of eugenol in relation to)
IT 97-53-0, Eugenol
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(anti-anaphylactic activity of)

L12 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2001 ACS
AN 1997:618647 CAPLUS
DN 127:298560
TI Odorless and nonirritant cosmetics containing eugenol and its derivatives
IN Yoshimura, Masanori; Watanabe, Yoji; Yoshiki, Mayumi; Takenaka, Gen; Yoshimune, Sadanori
PA Lion Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-00; A61K007-48; A61K031-09; A61K031-22; A61K031-60
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09241116	A2	19970916	JP 1996-75164	19960305

AB Title cosmetics, useful for improvement of blood circulation and treatment
of dropsy and myalgia, contain eugenol derivs. selected acetyleugenol (I),
methyleugenol, methylisoeugenol, ethyleugenol, ethylisoeugenol, and eugenol salicylate and 0.05-0.7 wt.% (based on the derivs.) eugenol (II). An odorless compn. contg. I 1.0, II 0.001, and EtOH 50.0 wt. parts was effective in treatment of dropsy. Formulation examples of aerosols and gels are given.
ST odorless cosmetic eugenol deriv dropsy treatment; myalgia treatment nonirritant cosmetic eugenol deriv; blood circulation improvement odorless cosmetic eugenol
IT Diseases (animal)
(dropsy, treatment of; odorless and nonirritant cosmetics contg. eugenol and its derivs. for blood circulation improvement)
IT Muscle diseases
(myalgia, treatment of; odorless and nonirritant cosmetics contg. eugenol and its derivs. for blood circulation improvement)
IT Blood flow
Cosmetics
Skin preparations (**pharmaceutical**)
(odorless and nonirritant cosmetics contg. **eugenol** and its derivs. for blood circulation improvement)
IT 93-15-2, Methyleugenol 93-16-3, Methylisoeugenol 93-28-7, Acetyleugenol 97-53-0, Eugenol 1755-54-0, Ethyleugenol 7784-67-0, Ethylisoeugenol 160431-51-6, Eugenol salicylate
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(odorless and nonirritant cosmetics contg. eugenol and its derivs. for blood circulation improvement)

L12 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2001 ACS
AN 1995:324830 CAPLUS
DN 122:89446
TI Pharmaceutical solutions containing essential oils for preparation of local anesthetics
IN Jamoulle, Jean Claude; Ballard, Philippe
PA Algovital SarL, Fr.
SO Fr. Demande, 7 pp.
CODEN: FRXXBL
DT Patent
LA French
IC ICM A61K035-78
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2704429	A1	19941104	FR 1993-5407	19930430
FR 2704429	B3	19950713		

AB An alk. soln. which contains essential oils is disclosed. The soln. is mixed with local anesthetics (e.g. lidocaine) for topical administration. A soln. contained Sepigel 2.5, Oramix 305 2.5, clove oil 10, menthol 10,

Ylang-Ylang oil 10, and NaOH N/10 q.s. 100%.
ST pharmaceutical soln essential oil local anesthetic; menthol clove oil local anesthetic soln
IT Essential oils
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(clove, pharmaceutical soln. contg. essential oils for prepn. of local anesthetics)
IT Essential oils
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(clove stem, pharmaceutical soln. contg. essential oils for prepn. of local anesthetics)
IT Castor oil
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated, pharmaceutical soln. contg. essential oils for prepn. of local anesthetics)
IT Anesthetics
(local, pharmaceutical soln. contg. essential oils for prepn. of local anesthetics)
IT Essential oils
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mint, Mentha, pharmaceutical soln. contg. essential oils for prepn. of
local anesthetics)
IT Fats and Glyceridic oils
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wheat germ, pharmaceutical soln. contg. essential oils for prepn. of local anesthetics)
IT Essential oils
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ylang-ylang, pharmaceutical soln. contg. essential oils for prepn. of local anesthetics)
IT 97-53-0, **Eugenol** 100-51-6, Benzyl alcohol, biological studies 1490-04-6, Menthol
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**pharmaceutical** soln. contg. essential oils for prepn. of local anesthetics)

L12 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2001 ACS
AN 1991:115063 CAPLUS
DN 114:115063
TI Eugenol-isoeugenol mixtures for treatment of AIDS
PA Kaempgen, Dieter, Fed. Rep. Ger.
SO Ger. Offen., 2 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM C07C043-23
ICS A61K031-085
CC 1-5 (Pharmacology)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3829200	A1	19900301	DE 1988-3829200	19880829

AB A compn. for treatment of AIDS contains engenol and isoengenol. Natural plant products contg. the compds., e.g. clove oil, may also be used. Treatment of AIDS patients with 2.5 mg clove oil/day resulted in complete elimination of disease symptoms and survival for .gtoreq.1 yr.
ST eugenol isoengenol AIDS treatment; clove oil AIDS treatment
IT Clove
(exts. of, for AIDS treatment)
IT Immunodeficiency
(acquired immune deficiency syndrome, treatment of, eugenol-isoeugenol mixt. in)
IT Oils, essential
FL: BIOL (Biological study)
(clove, AIDS treatment with)

IT **Pharmaceutical** dosage forms
(dragees, **eugenol**-isoeugenol mixt. in, for AIDS treatment)
IT **Pharmaceutical** dosage forms
(liqs., **eugenol**-isoeugenol mixt. in, for AIDS treatment)
IT **Pharmaceutical** dosage forms
(powders, **eugenol**-isoeugenol mixt. in, for AIDS treatment)
IT **Pharmaceutical** dosage forms
(tablets, **eugenol**-isoeugenol mixt. in, for AIDS treatment)
IT 91602-09-4
RL: BIOL (Biological study)
(AIDS treatment with)

L12 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2001 ACS
AN 1990:132456 CAPLUS
DN 112:132456
TI Eugenol enhancement of transdermal drug delivery
IN Leonard, Thomas W.; Mikula, Karol K.; Schlesinger, Marcia S.
PA American Home Products Corp., USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-045
NCL 514724000
CC 1-2 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4888362	A	19891219	US 1987-3983	19870116

AB Disclosed herein are compns. and methods for enhancing the transdermal delivery of physiol. active agents across mammalian skin or membranes and which comprise a precutaneous transfer enhancing amt. of eugenol and a drug. An enhanced percutaneous diffusion of albuterol through nude mouse skin from a formulation contg. 62% by wt. eugenol was demonstrated.
ST eugenol transdermal drug
IT Drug bioavailability
(from transdermal formulation, eugenol enhancement of)
IT **Pharmaceutical** dosage forms
(transdermal, **eugenol** as absorption potentiator for)
IT 97-53-0, **Eugenol**
RL: BIOL (Biological study)
(**pharmaceutical** transdermal absorption enhancement by)
IT 50-23-7, Hydrocortisone 18559-94-9, Albuterol
RL: BIOL (Biological study)
(transdermal absorption of, eugenol enhancement of)

L12 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2001 ACS
AN 1985:427328 CAPLUS
DN 103:27328
TI Ophthalmic pharmaceuticals
IN Oita, Nicolaie; Sunel, Valeriu; Vilcu, Ilarion; Lazar, Mihai; Calin, Ada; Baidan, Nastase
PA Intreprinderea de Medicamente "Biofarm", Rom.
SO Rom., 2 pp.
CODEN: RUXXA3
DT Patent
LA Romanian
IC A61K009-08; A61K009-06
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 84026	B	19840512	RO 1982-107359	19820426

AB An ophthalmic **pharmaceutical** comprises **eugenol** [97-53-0] 0.5-1.0, or methyleugenol [93-15-2], or clove oil, acetyl

rutoside [2328-13-4] 1-5, cysteine [52-90-4] 0.5-1.0, and MgCl2 0.5-1.0 g in ointment or soln.

ST ophthalmic **pharmaceutical** acetylrutoside **eugenol**; clove oil ophthalmic pharmaceutical

IT Oils
RL: BIOL (Biological study)
(clove, ophthalmic **pharmaceutical** contg. **eugenol** oil and)

IT 52-90-4, biological studies 93-15-2 97-53-0 2328-13-4
RL: BIOL (Biological study)
(ophthalmic pharmaceutical contg.)

IT 7786-30-3, biological studies
RL: BIOL (Biological study)
(ophthalmic **pharmaceutical** contg. **eugenol** and)

L12 ANSWER 23 OF 33 INPADOC COPYRIGHT 2001 EPO

LEVEL 1
AN 39857095 INPADOC
TI BACTERICIDAL **PHARMACEUTICAL** COMPOSITION CONTAINING CHLORHEXIDINE AND **EUGENOL**
IN LUC, JOELLE; TOSELLI, DOMINIQUE
INS LUC JOELLE; TOSELLI DOMINIQUE
INA FR; FR
PA PIERRE FABRE MEDICAMENT
PAS PF MEDICAMENT
PAA FR
LA French
DT Patent
PIT WOA1 PUBL.OF THE INT.APPL. WITH INT.SEARCH REPORT
PI WO 9309770 A1 19930527
DS RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE
W: CA JP US
AI WO 1992-FR1047 A 19921112
PRAI FR 1991-13919 A 19911113
OSCA 119:188673
OSDW 93-182218
ICM (5) A61K031-155
ICI (5) A61K031-155, (5) A61K031:085

L12 ANSWER 32 OF 33 PATOSWO COPYRIGHT 2001 WILA
AN 1993:168134 PATOSWO ED 19930620 EW 199321 FS OS
TI BACTERICIDAL **PHARMACEUTICAL** COMPOSITION CONTAINING CHLORHEXIDINE AND **EUGENOL**.
IN LUC, JOELLE, FR;
TOSELLI, DOMINIQUE, FR
PA PIERRE FABRE MEDICAMENT, FR
OS WLD1993024 WO 9309770 A1 0026
SO PCT-GAZETTE-930527
DT Patent
LA Application in French
DS W CA; W JP; W US;
RW AT; RW BE; RW CH; RW DE; RW DK; RW ES; RW FR; RW GB; RW GR; RW IE; RW IT; RW LU; RW MC; RW NL; RW SE
PIT WOA1 PCT-PUBLICATION
PI WO 9309770 A1 19930527
OD 19930527
AI WO 1992-FR1047 19921112
PRAI FR 1991-13919 19911113
IC ICM A61K031-155
ICI A61K031-155 A61K031:085.
ABEN The present invention relates to a bactericidal pharmaceutical composition caracterized in that it is comprised of a synergic association of chlorhexidine and eugenol.
FA ICI; INA; PAA; ABEN; PRAI

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 09:59:11 ON 17 JAN 2001

log hold

L8 ANSWER 2 OF 3 TOXLIT
AN 1991:3807 TOXLIT
DN CA-113-237854W
TI Topical pharmaceutical liquids containing indomethacin and solubility enhancers.
AU Inagi T; Inoue M; Muramatsu T
SO (1990). Jpn. Kokai Tokkyo Koho PATENT NO. 90196718 08/03/90 (Kohjin Co., Ltd.).
CY Japan
DT Patent
FS CA
LA Japanese
OS CA 113:237854
EM 199101
AB . . . topical pharmaceutical liq. contains 0.1-5% indomethacin 0.1-5 and 0.3-10% a soly. enhancer selected from limonene, pinene, camphene, citronellol, terpineol, camphor, **eugenol**, etc. Thus, a liq. **pharmaceutical** contained indomethacin 1.0, limonene 2.0, EtOH 50.0, diisopropanolamine 0.5%, and distd. **water** balance.